Andrew Wedlake
About Andrew Wedlake
Andrew Wedlake is a Senior Drug Discovery Data Scientist at Exscientia, where he has worked since 2023. He has extensive experience in cheminformatics and data science, having held positions at BenevolentAI and the University of Cambridge.
Work at Exscientia
Andrew Wedlake has been employed at Exscientia since 2023, serving as a Senior Drug Discovery Data Scientist. In this role, he leads the Property Prediction team, which specializes in machine learning methods for predicting potency, binding affinity, and ADME properties. His work contributes to advancing drug discovery processes through the application of data science techniques.
Previous Experience in Drug Discovery
Prior to his current position, Andrew Wedlake worked at Exscientia as a Discovery Data Scientist from 2021 to 2023. He also held the position of Cheminformatics Data Scientist at BenevolentAI from 2020 to 2021. During his time at BenevolentAI, he developed AI methodologies that were applied to live drug discovery projects and focused on QSAR models for biological activity and ADMET properties.
Postdoctoral Research Background
Andrew Wedlake completed a postdoctoral research position at the University of Cambridge in 2019, where he collaborated with Unilever on toxicology projects. His research emphasized high-performance and transparent predictions of biological activity, contributing to the understanding of toxicological impacts in drug development.
Education and Expertise
Andrew Wedlake earned a Master of Science in Natural Sciences from the University of Cambridge, completing his studies from 2011 to 2015. He further pursued a Doctor of Philosophy in Chemistry at the same institution, which he completed in 2019. His educational background provides a strong foundation in both natural sciences and chemistry, enhancing his expertise in drug discovery and cheminformatics.